Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$12.96
-4.0%
$0.00
$11.06
$63.00
$253.37M1.5228,628 shs293,259 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$2.50
+1.8%
$1.72
$0.73
$3.90
$158.23M0.7414,699 shs356,228 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.74
+5.8%
$1.67
$1.15
$3.47
$12.13M-0.3422,200 shs2,556 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$0.23
-0.4%
$0.26
$0.15
$3.10
$2.71M1.35.28 million shs5.23 million shs
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$1.13
-12.8%
$0.98
$0.78
$5.15
$38.45M1.57440,137 shs841,344 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-8.72%-15.04%-98.24%-98.24%-98.24%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
+8.89%+13.69%+82.84%+81.48%+4.70%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-2.17%-1.47%-6.94%+15.52%-49.70%
Heatwurx Inc. stock logo
PCSA
Heatwurx
-5.31%+19.12%-33.07%-7.60%-86.56%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
+8.40%+50.35%+25.24%+21.70%-33.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.5142 of 5 stars
3.80.00.03.73.21.70.6
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
1.6086 of 5 stars
3.50.00.00.02.41.70.0
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
4.1381 of 5 stars
3.04.00.04.61.90.01.3
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.8366 of 5 stars
3.55.00.00.03.31.71.3
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
4.1879 of 5 stars
3.73.00.04.13.30.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.67
Strong Buy$25.0092.90% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.00140.48% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00188.18% Upside
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.00
Buy$2.00773.36% Upside
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.33
Buy$4.00255.56% Upside

Current Analyst Ratings Breakdown

Latest NERV, RMTI, CBIO, PCSA, and GALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $2.00
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K25,336.80N/AN/A$8.24 per share1.57
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.21 per share8.19($3.67) per shareN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A$0.46 per shareN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$97.73M0.39$0.12 per share9.41$1.01 per share1.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.12N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$11.85M-$3.08N/AN/AN/AN/A-319.56%-232.40%8/12/2025 (Estimated)
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$480KN/A0.00N/AN/A-0.27%-0.90%-0.47%8/14/2025 (Estimated)

Latest NERV, RMTI, CBIO, PCSA, and GALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
5/12/2025Q1 2025
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$0.03-$0.04-$0.01-$0.04$17.46 million$18.91 million
5/8/2025Q1 2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$0.77-$0.30+$0.47-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
0.08
0.08
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
2.93
2.93
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
0.30
2.95
2.50

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
23.31%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million18.77 millionNo Data
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.58 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
96.99 millionN/ANot Optionable
Heatwurx Inc. stock logo
PCSA
Heatwurx
2011.88 million10.74 millionNot Optionable
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
30034.18 million32.95 millionOptionable

Recent News About These Companies

Rockwell Medical Inc
Q1 2025 Rockwell Medical Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$12.96 -0.54 (-4.00%)
As of 03:39 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$2.50 +0.05 (+1.84%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.74 +0.10 (+5.79%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$0.23 0.00 (-0.39%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Rockwell Medical stock logo

Rockwell Medical NASDAQ:RMTI

$1.12 -0.17 (-12.79%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.